Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jan 30;16(4):578–590. doi: 10.1158/1535-7163.MCT-16-0606

Figure 5. HJC0152 slows HNSCC tumor growth and suppressed local invasion in vivo.

Figure 5

(A) Representative bioluminescence images comparing HJC0152-treated (7.5 mg/kg) orthotopic HNSCC tumors with DMSO-treated controls every week for 4 weeks (BLI: bioluminescence imaging, P < 0.05). (B) Representative images for orthotopic tumors of HJC0152 or DMSO treated animals. (C) Based on body weight, no detectable toxicity was observed at the tested dose (7.5 mg/kg) (error bars indicate standard deviation). (D) A TUNEL assay showed more induced apoptotic nuclei in HJC0152-treated tumor cells (7.5 mg/kg) than in DMSO-treated cells (Scale bar, 30 μm). (E) Representative photographs of the tumor resection procedure. HJC0152 (7.5 mg/kg) significantly inhibited local invasion of orthotopic HNSCC tumors. In each group, the first two photographs represent the original orthotopic tumor while the last two photographs represent the local invasion situation during and after resection, respectively. (F) HJC0152 (7.5 mg/kg) significantly inhibited cervical lymph node metastasis of orthotopic HNSCC tumors. * P < 0.05, *** P < 0.001.